The device is for screening of arterial stiffness and for the diagnosis of cardiovascular diseases such as arterial stenosis and heart failure.
Cardiovascular disease (CVD) is among the leading causes of death globally and early identification allows for intervention to halt or reverse the pathological process. Assessment of arterial stiffness by measurement of aortic pulse wave velocity (aPWV)
is included in the latest guidelines for CVD risk prediction and it is a key marker for hypertension.
However, no tools are available that are able to easily screen a large number of patients for arterial stiffness at a GP’s office. As a consequence, many individuals remain undiagnosed.
In this Horizon 2020 project CARDIS, imec, Medtronic, and 7 other partners, have developed a prototype mobile, low-cost, point-of-care screening device for CVD. The device aims for measurement in a fast, reproducible and reliable way with minimal physical contact with the patient and minimal skills from the operator.
The operating principle of the device is Laser Doppler Vibrometry (LDV), in which a very low-power laser is directed towards the skin overlying an artery. The skin’s vibration amplitude and frequency, resulting from the heart beat, are extracted from the Doppler shift of the reflected beam. The device includes two rows of six beams, thereby scanning multiple points on the skin above the artery in parallel.
At the heart of the system is a silicon photonics chip containing the optical functionality of the multi-beam LDV device. The CARDIS chip was designed by the Photonics Research Group, an imec laboratory at Ghent University, and prototyped through imec’s silicon photonics technology platform iSiPP50G, and has been implemented using advanced optical packaging approaches developed at the Tyndall National Institute in Ireland. The system has then been integrated into a handheld device and validated for human use by Medtronic.
A clinical feasibility study at the Georges Pompidou European Hospital has collected a substantial clinical dataset, both from healthy subjects as well as from patients with cardiovascular conditions. The quality of the device readings was found to be very good and adequate measurement results could be obtained in all subjects. In-depth analysis will be performed both at INSERM and at the biomedical engineering department of Ghent University with the support of Medtronic. Moreover, further clinical feasibility studies are planned in the Academic Hospital of Maastricht (The Netherlands).
Commenting Roel Baets, head of the Photonics Research Group (imec/UGent), said: “Silicon photonics is a powerful technology that combines the unique sensing capabilities of photonics with the low-cost and miniaturisation capabilities of silicon semiconductor technology. It’s exciting to know that our silicon photonic chip and prototype medical device hold the promise to change the lives of so many patients with cardiovascular diseases.”
In a next step, a small series of the device will be produced to perform a clinical feasibility study on a larger group of patients and over a longer period of time. If this study demonstrates the
ability of the technology to detect cardiovascular diseases at an early stage, high volume production can be initiated.
